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Efficient replication of hepatitis C virus (HCV) subgenomic RNA in cell culture requires the introduction of
adaptive mutations. In this report we describe a system which enables efficient replication of the Con1 sub-
genomic replicon in Huh7 cells without the introduction of adaptive mutations. The starting hypothesis was
that high amounts of the NS5A hyperphosphorylated form, p58, inhibit replication and that reduction of p58
by inhibition of specific kinase(s) below a certain threshold enables HCV replication. Upon screening of a panel
of kinase inhibitors, we selected three compounds which inhibited NS5A phosphorylation in vitro and the
formation of NS5A p58 in cell culture. Cells, transfected with the HCV Con1 wild-type sequence, support HCV
RNA replication upon addition of any of the three compounds. The effect of the kinase inhibitors was found to
be synergistic with coadaptive mutations in NS3. This is the first direct demonstration that the presence of high
amounts of NS5A-p58 causes inhibition of HCV RNA replication in cell culture and that this inhibition can be
relieved by kinase inhibitors.
The hepatitis C virus (HCV) has been identified as one of
the major causes of chronic liver disease, and neither vaccines
nor broadly effective therapeutic agents are available (7). HCV
contains a plus-strand RNA genome which encodes a single
polyprotein precursor that is cleaved by cellular and viral pro-
teases (1, 23). The structural proteins core, E1, and E2 are
located in the amino terminus of the polyprotein (11), followed
by p7, a hydrophobic peptide capable of forming an ion chan-
nel (10, 21), and the nonstructural (NS) proteins NS2, NS3,
NS4A, NS4B, NS5A, and NS5B, which are putative components
of the RNA replication machinery (6). NS5A is a 446-amino-
acid phosphoprotein which is phosphorylated on many serine
residues and exists in two distinct species, termed p56 (phos-
phorylated) and p58 (hyperphosphorylated). In p56, two of the
modified serine residues have been identified as serine residue
2194 in strain 1B (13) and serine residue 2321 in strain 1A (22).
In addition to these basal phosphorylation sites, three serine
residues, S2197, S2201, and S2204, have been reported to be im-
portant for hyperphosphorylation (25). The hyperphosphory-
lation of NS5A is a highly regulated process which requires the
expression of an intact NS3-5A polyprotein and correct poly-
protein processing (14, 20). The family of cellular kinase(s)
responsible for NS5A phosphorylation has been identified as
the CMGC group of serine-threonine kinases (24).
Studies of HCV biology and the elucidation of the function
of the single viral protein has been slowed down for a long time
by the lack of a permissive cell culture system supporting the
efficient replication of the virus. Some years ago, however,
Lohmann and colleagues reported efficient HCV replication in
the human hepatoma cell line Huh7 after transfection of a bi-
cistronic subgenomic replicon expressing a selectable marker
(18). Replication of this replicon dramatically increases after
the occurrence of adaptive mutations, which map predominant-
ly in NS5A and, in some cases, affect its phosphorylation status
(2, 16).
The fact that many adaptive mutations reside in NS5A sug-
gests a role for NS5A or its different phosphorylated forms in
RNA replication, even though the exact mechanism is still
obscure. It is interesting that the most effective adaptive mu-
tations, with the exception of those in NS4B, map exactly at
serine residues, which have been implicated in NS5A hyper-
phosphorylation (2). Adaptive mutations at these sites result in
a significant reduction of NS5A p58 formation. This observa-
tion suggests not only that NS5A hyperphosphorylation is not
necessary for HCV replication in cell culture but that it seems
that it may be deleterious.
The replicon system would be an ideal system for the study
of HCV replication mechanisms. It has been noted, however,
that mutations that are adaptive for replication of HCV in cell
culture are highly attenuated in vivo (4). The HCV-N strain
seems to be an exception. It has been reported that HCV-N is
infectious in the chimpanzee model and that it is able to rep-
licate efficiently in cell culture without any adaptive mutation
(12). However, NS5A derived from this HCV strain contains a
natural insertion of 4 amino acids, which is unique to this
isolate compared to all other viral strains. This 4-amino-acid
insertion renders the corresponding replicon highly efficient
for replication in cell culture, and at the same time, infectivity
in the chimpanzee model is maintained. Viremia in the in-
fected chimpanzee, however, is at a low level, and subsequent
infection of two other chimpanzees with RNA derived from
the primary infected chimpanzee failed (12). Thus, it seems
that the 4-amino-acid insertion significantly attenuates infec-
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tivity in the chimpanzee and functions as a naturally occurring
cell culture-permissive variant.
It is of great importance to develop a cell culture system in
which HCV replicates without losing its in vivo infectivity po-
tential. In this case, the cell culture system could be considered
a better mimic of in vivo replication.
In this work, we show that compounds that inhibit the for-
mation of NS5A p58 by inhibition of the putative kinase(s)
render a nonadapted HCV replicon capable of replication in
cell culture.
MATERIALS AND METHODS
Plasmid construction. DNA plasmids used in this work were constructed by
standard recombinant DNA technology, and the correct sequence was confirmed
by automated nucleotide sequencing. Amino acid numbers refer to the location
of the Con1 full-length HCV genome (EMBL accession number AJ238799)
starting from the core coding region. The DNA plasmids wild type (wt) and m17
have been previously described as pHCVNeo17.wt and pHCVNeo17.C, respec-
tively (27). The other plasmids are identical to pHCVNeo17.wt but contain the
following mutations: SA, S2204A in NS5A; m17/SA, S2204A in NS5A and
E1202G in NS3; m17-GAA, E1202G in NS3 and D2737A/D2738A in NS5B;
wt-GAA, D2737A/D2738A in NS5B. For the experiment for which results are
shown in Fig. 3, the neomycin phosphotransferase (neo) gene of plasmid wt and
SA was replaced by the -lactamase (BLA) gene as described previously (19),
resulting in plasmids wt-BLA and SA-BLA, respectively.
In vitro kinase assay. Huh7 cells containing the Con1 subgenomic replicon
with the adaptive mutation A2199T (Huh7-68) were grown to 50% confluence,
and the protein extract was prepared as follows. Cells from a 15-cm-diameter
dish were lysed with 500 l of NETN buffer (50 mM Tris-HCl [pH 7.5], 120 mM
NaCl, 1 mM EDTA, 0.5% NP-40) supplemented with 5 mM dithiothreitol
(DTT), 2 mM phenylmethylsulfonyl fluoride, 100 mM NaF, 20% glycerol, and
the protease inhibitor cocktail Complete (Roche) as described previously (24).
For immunoprecipitation, 2.5 l of NS5A-specific antibody (20) was bound to 12
l of protein A-Sepharose in 300 l of NETN for 1 h at 4°C. After the incuba-
tion, protein A-Sepharose was washed once with NETN and 30 g of total
protein was immunoprecipitated in 300 l of NETN for 1 h at 4°C. After binding,
the resin was washed once with NETN supplemented with 5 mM DTT and once
with kinase buffer (50 mM Tris-HCl [pH 7.5], 5 mM MnCl, 5 mM DTT, and 50
mM NaF). For the in vitro kinase reaction, 50 l of kinase buffer supplemented
with 2.5 Ci of [-33P]ATP and 2.5 l of either 100 M compound dissolved in
dimethyl sulfoxide (DMSO; final concentration, 5 M) or DMSO alone was
added to the immunoprecipitate. Reaction mixtures were incubated for 45 min
at 37°C, and the reaction was terminated by the addition of 25 l of 3 protein
sample buffer. Proteins were loaded onto a sodium dodecyl sulfate (SDS)–7.5%
polyacrylamide gel electrophoresis (PAGE) gel and autoradiographed.
Cell culture and BLA assay. Huh-7 and Huh7-68 were cultured in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine serum. For cells
supporting subgenomic replicons, 0.8 mg of G418 (Geneticin; Gibco-BRL)/ml
was added. Cells highly competent for HCV replication (10A-IFN) were ob-
tained by curing HBI10A cells from the endogenous replicon with human al-
pha-2b interferon as described previously (27). The BLA assay was performed as
described previously (19). For microscopy, cell fluorescence was observed by
excitation of CCF2 through a 405-nm-pore-size filter with emission at 460 nm
(blue fluorescence) or 515 nm (green fluorescence). Fluorescence microscopy
was conducted on live 10A-IFN cells with a Leica DMIL microscope, and images
were taken with a digital camera (Nikon CoolPix 995).
RNA transfection and protein expression with the vaccinia infection-transfec-
tion system. RNA transcripts were prepared by using pHCVNeo17 plasmids
digested with ScaI and the Megascript kit (Ambion) exactly as described previ-
ously (27). Ten micrograms of RNA was electroporated in 106 10A-IFN cells
with the GenePulser XCell (Bio-Rad) at 110 V for 25 ms. After electroporation,
2.5  105 cells (5  105 when incubated with compound F495) were plated in a
35-mm-diameter dish and incubated for 4 days in the presence or absence of 8
M compound as described in the figure legend. The RdRP inhibitor RdRP-I
corresponds to compound 1 described elsewhere (26). Protein expression with
the vaccinia infection-transfection system was performed as described previously
(20). Cells (3.5  105 10A-IFN cells/35-mm-diameter dish) were plated the day
before the experiment. Two micrograms of pHCVNeo17 plasmid was transfected
by using Fugene6 (Roche) as the transfection reagent.
Metabolic labeling of proteins and immunoprecipitation. Metabolic labeling
of proteins and immunoprecipitation was performed as described previously
(20). To assess the inhibitory activity of the compounds, cells were preincubated
with 5 M concentrations of the indicated compounds for 1 h before starvation
and labeling and were present during the whole time of labeling. Cell extraction
and denaturing immunoprecipitation were performed as described previously
(20).
Quantitative TaqMan RT-PCR. RNA was prepared by using the RNeasy mini
kit (QIAGEN) as described by the manufacturer. The final volume was 100 l of
RNA/35-mm-diameter dish. Two microliters of RNA was used for quantitative
reverse transcription (RT)-PCR by using an ABI PRISM 7900 HT sequence
detector (Applied Biosystems). Amplifications were performed in duplicate with
the TaqMan one-step RT-PCR master mix reagent kit (Applied Biosystems).
Oligonucleotides and probe annealed in the 5 untranslated region of HCV. The
primers (450 nM) are GP5, 5-CGGGAGAGCCATAGTGG-3, and GP6, 5-A
GTACCACAAGGCCTTTCG-3. The probe contains the 6-FAM dye at the 5
end and the TAMRA quencher at its 3 end. The HC2 probe (150 nM) is 5-6-
FAM–CTGCGGAACCGGTGAGTACAC–TAMRA-3. As an endogenous stan-
dard, we used the -actin probe, containing the VIC dye at its 5 end (Applied
Biosystems). Reactions were conducted in three stages under the following
conditions: stage 1, 30 min at 48°C; stage 2, 10 min at 95°C; stage 3, 15 s at 95°C
and 1 min at 60°C for 40 cycles. The total volume of the reaction mixture is 50 l.
Compounds. Compound SB203580 was purchased from Calbiochem. Com-
pounds H479, A852, and F495 were synthesized in-house and are available for
research purposes upon request.
RESULTS
In vitro inhibition of NS5A phosphorylation by protein ki-
nase inhibitors. To identify compounds that inhibit the forma-
tion of NS5A p58, we set up an in vitro assay which allowed the
screening of several hundred compounds for their inhibitory
activity on NS5A phosphorylation. As a source of compounds,
we used a collection of proprietary kinase inhibitors with the
general structure of ATP-competitive 2,4,5-trisubstituted imi-
dazole inhibitors.
NS5A was expressed in Huh7-68 cells, and cell extract was
prepared as described in Materials and Methods. It has previ-
ously been reported that cellular kinases remain associated
with NS5A after immunoprecipitation with specific anti-NS5A
antibodies (24). In this study, we incubated the cell extract with
an NS5A-specific antibody and immunoprecipitated the asso-
ciated protein complex under native conditions. The immuno-
precipitated proteins were then incubated with [-33P]ATP in
the presence or absence of 5 M compound. After the reac-
tion, phosphorylated proteins were resolved by SDS-PAGE,
and the results are shown in Fig. 1. Comparison of the non-
specific phosphoproteins present in Huh7 cells not expressing
the replicon (lane 2) with those obtained from the replicon
cells Huh7-68 (lane 3) clearly indicated the production of
phosphorylated NS5A. Most of the phosphates were incorpo-
rated into p56, even though a small quantity was visible also in
p58 (lanes 3, 4, 6, and 7). Many compounds of the collection
had no or only little effect on any of the kinases present in the
immunoprecipitation (lanes 4 and 6). A large number of com-
pounds, around 40%, showed 50% or more inhibition. Exam-
ples of compounds that inhibited more than 80 to 90% are
shown in lanes 5, 8, and 11 to 13, whereas compounds with
intermediate inhibition of NS5A phosphorylation are shown in
lanes 7, 9, and 10. Besides NS5A-specific inhibition of phos-
phorylation, other proteins present in the immunoprecipitate
were inhibited to different extents by different compounds,
pointing to the presence of more than one protein kinase in the
immunoprecipitate. For example, SB203580, a specific inhibi-
tor of the mitogen-actived protein kinase p38 (5), inhibited the
phosphorylation of all proteins, including NS5A, by more than
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50%. SB203580 was thus used throughout the study as a non-
specific control protein kinase inhibitor.
We selected all compounds which inhibited NS5A phosphor-
ylation by more than 50% and monitored their activity in a
cell-based assay described below.
Inhibition of NS5A phosphorylation in cell culture by se-
lected compounds. All selected compounds were evaluated in
cell culture to assess their effects on NS5A phosphorylation in
the context of live cells and active HCV polyprotein processing
by using the vaccinia T7 infection-transfection system. DNA
plasmid coding for the wt Con1 HCV replicon was transfected
into Huh7 cells, and viral proteins were labeled with [35S]me-
thionine, to monitor protein expression, or with [32P]ortho-
phosphate, to investigate phosphorylation efficiency (Fig. 2A).
Most of the selected compounds had no effect on NS5A phos-
phorylation in cell culture or affected the expression of NS5A
and the other viral proteins without changing the phosphory-
lation pattern (data not shown). Three compounds selectively
inhibited the formation of the p58 form of NS5A (Fig. 2A,
lanes 3 to 5 and 9 to 11). Conversely, no compound was iden-
tified which inhibited basal NS5A phosphorylation without af-
fecting NS5A expression. Like many other compounds, the con-
trol compound SB203580 inhibited the in vitro phosphorylation
of NS5A by more than 50% (Fig. 1) but had no effect either on
protein expression or on protein phosphorylation in cells.
The vaccinia T7 infection-transfection system can be used to
study protein phosphorylation during active HCV polyprotein
expression and processing. During active HCV replication,
however, localization of viral proteins and protein-protein in-
teractions may differ from the vaccinia T7 infection-transfec-
tion system, and therefore, the susceptibility of the specific
kinase for the inhibitors may change. We incubated Huh7-68
cells with the three indicated compounds and labeled the pro-
teins either with [35S]methionine or with [32P]orthophosphate
(Fig. 2B). The results obtained were identical to those already
observed with the vaccinia T7 infection-transfection system.
Inhibition of NS5A hyperphosphorylation by the three selected
kinase inhibitors was further confirmed to not depend on a
specific replicon sequence by using cells carrying a replicon
that contained an insertion of a lysine after valine 2039
(K@2039) (27), i.e., more than 150 amino acids away from the
hyperphosphorylation sites. Also, in this case, the formation of
p58 was efficiently inhibited (data not shown).
FIG. 1. Inhibition of NS5A phosphorylation in vitro. NS5A was im-
munoprecipitated from Huh7-68 cells and incubated with [-33P]ATP
as described in Materials and Methods. The phosphorylation of NS5A
in the absence (lane 3) or presence of 5 M concentrations of different
compounds (lanes 4 to 13) is shown. As a control, proteins were im-
munoprecipitated from Huh7 cells (lane 2); the sizes of molecular
mass marker proteins are indicated in lane 1. Proteins were loaded on
SDS-PAGE gels, and the autoradiogram is shown.
FIG. 2. Inhibition of NS5A p58 formation in cell culture. (A) NS5A
was expressed by using the vaccinia infection-transfection system. The
plasmid wt-BLA was transfected for 4 h in 10A-IFN cells, and proteins
were labeled either with [35S]methionine (lanes 2 to 6) or with [32P]
orthophosphate (lanes 8 to 12) in the presence of DMSO (lanes 2 and
8) or with a 5 M concentration of compound H479 (lanes 3 and 9),
A852 (lanes 4 and 10), F495 (lanes 5 and 11), or SB203580 (lanes 6 and
12). After radiolabeling, the protein extract was prepared, NS5A was
immunoprecipitated, and proteins were loaded onto an SDS–7.5%
PAGE gel and autoradiographed as described in Materials and Meth-
ods. (B) The same type of experiment was performed with Huh7-68
cells. The sizes of molecular mass marker proteins (M) are indicated in
lanes 1 and 7.
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Activation of replication of wt Con1 replicon in the presence
of kinase inhibitors. Having identified compounds that specif-
ically inhibit NS5A hyperphosphorylation, we tested their ef-
fects on HCV replication in cell culture.
To this aim, we used a subgenomic replicon in which the
original neomycin phosphotransferase (neo) gene was replaced
by the BLA gene (bla) (19). Cells actively replicating HCV
express BLA and show a blue staining after incubation with a
diffusible BLA substrate (BLA assay). Replicon RNA was
electroporated in 10A-IFN cells, and compounds were added
at a concentration of 8 M 2 h after electroporation. The BLA
assay was performed after 4 days of incubation, and results
are shown in Fig. 3. As a positive control, we used a replicon
containing the adaptive mutation S2204A (SA-BLA). This
adaptive mutation reduces the formation of NS5A p58, similar
to the already published mutation S2204I (Fig. 4A).
Electroporation of the wt Con1 replicon did not generate
any blue cells (Fig. 3, wt-BLA), whereas the addition of any of
the three compounds resulted in the production of blue cells as
a consequence of HCV replication (Fig. 3, wt-BLA  com-
pound). The three selected kinase inhibitors, however, did not
induce replication to equal efficiencies. Whereas compound
H479 produced more than 50% blue cells, which is comparable
to the positive control, the other two compounds generated
fewer blue cells. The control compound SB203580 had no ef-
fect on HCV replication. To demonstrate that the blue staining
is a result of HCV replication and not a result of a longer half
life of the electroporated HCV RNA or BLA enzyme, we in-
cubated the cells, in addition to the compounds, with an inhib-
itor of the HCV RNA-dependent RNA polymerase (RdRP)
( RdRP-I, right column) (8, 26). In all cases, the numbers of
blue cells are significantly reduced. In the case of compound
F495, some blue cells remain even in the presence of the RdRP
inhibitor. It would be possible that compound F495 stabilizes
the HCV RNA and consequently BLA expression to some
extent (Fig. 3 and 4B).
Synergistic effect between mutation in NS3 and identified
kinase inhibitors. The advantage of the BLA assay is its de-
tection of single cells in which active HCV replication takes
place. As a result, HCV replication can be observed also in
cases in which only a small percentage of the overall cell
population is capable of replication. The previous experiment
shows that all three compounds induce the replication of the
wt Con1 replicon. We next investigated whether replication is
sufficient to allow the detection of viral proteins or viral RNA
in the total cell population. RNA of wt Con1 replicon was
electroporated into 10A-IFN cells, and compounds were
added 2 h after electroporation. After 4 days of incubation,
cells were collected and cellular extracts were assayed for the
presence of NS5A by immunoblotting (Fig. 4A) or for HCV
RNA by quantitative PCR (Fig. 4B). As expected, no NS5A
was visible in untreated cells or in cells incubated with the
control inhibitor SB203580 (Fig. 4A, lanes 15 and 19). Inter-
estingly, NS5A could be detected only in the presence of com-
pound H479, whereas no or little protein was visible in cells
treated with compound A852 or F495 (compare lane 16 with
lanes 17 and 18), even though compounds A852 and F495
induced replication (Fig. 3). A possible explanation for this
finding is that the replication efficiency, and thus the quantity
of viral proteins induced by A852 and F495, is lower than that
for H479. Nonetheless, due to the extremely high sensitivity of
the BLA assay, sustained low-level replication could be re-
vealed by blue cell staining after prolonged incubation of the
cell with the BLA substrate.
During the characterization of the replicon, several muta-
tions have been identified that are synergistic to adaptive mu-
tations, thus increasing the replication efficiency (15, 27). One
of these mutations is E1202G, which maps in NS3 (in this work
described as m17). By itself, this mutation has little, if any,
effect in promoting replication of the Con1 replicon (Fig. 4A,
lanes 2 and 5). However, it has a strong synergistic effect on
replication when combined with the S2204A mutation (Fig.
4A, compare lanes 3 and 4).
We thus investigated whether the mutation E1202G in NS3
acted synergistically with the kinase inhibitors in a similar way
to what was observed with the adaptive mutation (lanes 5 to 9).
All three compounds activated replication of the replicon m17,
with compound H479 being the most potent activator and
compound F495 being the least potent activator. The synergis-
tic effect of the mutation in NS3 with the adaptive mutation in
NS5A (lane 3 and 4) is comparable to its synergistic effect with
the kinase inhibitors (compare lanes 16 to 18 with lanes 6 to 8).
The presence of NS5A is clearly due to active HCV replication
FIG. 3. Induction of replication of the Con1 wt subgenomic repli-
con in the presence of kinase inhibitors. RNA was transcribed from
plasmid wt-BLA or SA-BLA, and 10 g of RNA was transfected into
10A-IFN cells as described in Materials and Methods. Cells were
incubated for 4 days with or without 8 M compound (left column) or
with or without compound plus 30 M RdRP inhibitor RdRP-I (right
column). The results shown are from the BLA assay, in which blue cell
staining indicates active HCV replication.
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and not to protein stabilization because replicons containing
the RdRP-inactivating mutation GAA (17) do not show any
detectable NS5A protein (lanes 10 to 14).
Compounds which induce replication of wt replicons or m17
have an opposite effect on the replication of already adapted
replicons. Replication of the replicon SA is completely inhib-
ited at a 2 M concentration of compound A852 (Fig. 4A,
lanes 20 to 25) (also see Discussion).
The production of HCV-specific RNA was detected by real-
time RT-PCR amplification (Fig. 4B). The expression of -ac-
tin was used as an internal control to standardize for the total
amount of RNA. The induction of HCV-RNA with respect to
the DMSO control is shown. Compound H479 induced the
replication of the wt Con1 replicon sixfold, as measured by
quantitative PCR, whereas induction of replication by the
other compounds was below the background (that of the wt).
As already observed in Fig. 4A for protein expression, cells
supporting subgenomic replicons with the synergistic mutation
in NS3 (m17) contain significantly more HCV RNA upon
incubation with the kinase inhibitors than those expressing the
wt Con1 replicon. Replication is induced 312-fold for com-
pound H479, 58-fold for compound A852, and 30-fold for
compound F495. The presence of HCV RNA is due to active
replication, as the HCV RNA polymerase-minus mutants (wt-
GAA and m17-GAA) do not show any induced amount of
RNA. One exception is compound F495, which induces a slight
increase of RNA even without active HCV replication. The same
observation was already made by using the BLA assay (Fig. 3).
DISCUSSION
Since the identification of adaptive mutations in the HCV
subgenomic replicon, it has been noted by several groups that
the hyperphosphorylated form of NS5A, p58, is not necessary
for replication in cell culture. In this report, we go one step
further and demonstrate that high quantity of p58 is not only
FIG. 4. Detection of HCV-specific proteins or HCV RNA after
induction or inhibition with the specific kinase inhibitors. RNA was
transcribed from the plasmids wt, wt-GAA, m17, SA, m17/SA, and
m17-GAA and electroporated into 10A-IFN cells as described in Ma-
terials and Methods. Cells were incubated for 4 days without (red bar)
or with 8 M concentrations of compound H479 (blue bar), compound
A852 (green bar), compound F495 (black bar) or SB203580 (pink bar).
(A) Western blot analysis of total protein extracts. Cell extract was
prepared as described in Materials and Methods, and 50 g of protein
was loaded for each lane. Specific anti-NS5A (lanes 2 to 19) or anti-
NS3 (lanes 20 to 25) antibodies were used as primary antibodies, and
a peroxidase-conjugated antibody (Pierce) was used as a secondary
antibody. The Western blot was developed by using the SuperSignal
West Pico chemiluminescent substrate (Pierce). (B) HCV-specific RNA
analysis by quantitative RT-PCR. Total cellular RNA was extracted,
and HCV-specific RNA was quantified as described in Materials and
Methods. Induction with respect to the DMSO control is shown on the
y axis. Replicon RNA is indicated at the bottom of the figure.
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not necessary but also deleterious for the replication of the
Con1 replicon. To demonstrate this hypothesis, we prevent the
formation of NS5A p58 by chemical means, without altering
the wt sequence of the Con1 HCV genome.
An in vitro assay was set up which enabled us to screen a
collection of small molecules for their inhibitory activity on ki-
nase(s) responsible for NS5A phosphorylation. The principle
of this in vitro assay is based on the fact that the specific ki-
nase(s) remain stably associated with NS5A after immunopre-
cipitation. Incubation of this protein complex with [-33P]ATP
results in the production of many phosphoproteins (Fig. 1),
indicating that the polyclonal antibody nonspecifically binds
many cellular proteins and kinases under the conditions we
used for the immunoprecipitation. However, the phosphoryla-
tion of NS5A is the most efficient reaction in the immunopre-
cipitate prepared from extracts expressing the replicon (Fig. 1,
compare lanes 2 and 3). In replicons containing the A2199T
adaptive mutation, p56 and p58 are present in equal amounts
(Fig. 2B, lane 2). Nevertheless, in the in vitro assay, radiola-
beled phosphate is incorporated predominantly in p56. The
formation of p58 depends on the presence of the HCV poly-
protein coding from NS3 to NS5A and requires active poly-
protein processing (14, 20). For this reason, the formation of
p58 during in vitro labeling is not expected. In addition, one
can imagine that the conformation of p58 is different from that
of p56 and that phosphorylation sites present in p56 are not
exposed or masked by other associated proteins in p58. As a
consequence, the in vitro phosphorylation of serine residues in
p56 may be more efficient than in p58.
The low stringency of the assay produced a hit rate of about
40%, with a threshold of at least 50% inhibition of NS5A
phosphorylation. As a consequence, a large number of com-
pounds showed the same in vitro activity as the three selected
compounds but were inactive in cell culture. There are several
explanations for the difference between in vitro activity and
activity in cell culture. One possibility could be limited pene-
tration of the compounds into the cells. Alternatively, a high
potential of the compounds for protein binding or instability in
the culture medium or within the cell could limit the access to
the compound. All compounds tested were designed to be
active-site inhibitors and competitors of ATP. Another possi-
ble explanation would be that the affinity of the compound for
the kinase is too low to compete with the relatively high con-
centrations of ATP within the cell.
Retesting the selected compounds in cell culture with the
vaccinia T7 infection-transfection system as well as Huh7-68
cells identified three active compounds. The formation of p58
is inhibited in both systems, whereas the basal phosphorylation
of p56 remained unchanged (Fig. 2A and B, lanes 8 to 12).
Interestingly, we could not identify any compound that inhib-
ited the basal phosphorylation without affecting the expression
of NS5A. NS5A is proteolytically processed from the polypro-
tein within 15 min (20). The prevention of basal phosphor-
ylation may destabilize the protein and lead to protein deg-
radation. In this case, any compound which inhibits basal
phosphorylation would reduce the total protein amount of
NS5A and would have been excluded in our second assay in
cell culture.
The identification of three compounds that selectively inhib-
ited NS5A hyperphosphorylation, but not basal phosphoryla-
tion, allowed us to verify whether a reduction of the amount of
NS5A p58 in the context of the Con1 wt sequence could be
sufficient for the activation of subgenomic replication in cell
culture. It turned out, in fact, that all three active kinase in-
hibitors were also active replication inducers (Fig. 3).
Compound H479 is the best inhibitor, as it activates repli-
cation in more than 50% of the cells. This efficiency is compa-
rable to the S2204A adaptive mutation, resulting in the expres-
sion of HCV proteins at levels detectable by Western blotting.
Consistent with the inhibition of NS5A hyperphosphorylation,
the formation of p58 is significantly reduced (Fig. 4A, lane 16).
It is important to stress the point that the only difference which
renders the replicon capable of replication is the reduction of
p58 formation by a kinase inhibitor without changing the ge-
nomic sequence. Thus, an excess amount of p58 seems to be
the causative agent responsible for the inhibition of HCV rep-
lication in cell culture.
The other two compounds also activated replication (Fig. 3);
however, HCV proteins and HCV RNA were detectable only
in the presence of a synergistic mutation in NS3 (Fig. 4). The
introduction of mutations may be critical for infectivity, as
shown in the case of adaptive mutations. These mutations
increase HCV replication efficiency in cell culture, but at the
same time, they destroy or significantly attenuate infectivity in
vivo (4). One, therefore, has to carefully choose any change in
the wt sequence. In this work, we decided to introduce the
mutation E1202G in NS3. This mutation has been shown to
increase the replication efficiency of the Con1 subgenome
when placed together with the adaptive mutations S2197P,
K@2039, S2204I (15, 16, 27), and S2204A (Fig. 4) in NS5A.
The advantage of the E1202G mutation is the fact that it has
been found as a naturally occurring mutation in an infective
clone of the 1A strain, thus suggesting that this mutation does
not destroy infectivity in vivo (28). The E1202G mutation is
synergistic when placed together with adaptive mutations at
the hyperphosphorylation site of NS5A and is therefore an
ideal candidate for synergistic effects in the presence of the
kinase inhibitors.
Replicons containing the E1202G substitution in NS3 (m17)
do replicate with low efficiency, and HCV proteins cannot be
detected by Western blotting (Fig. 4A). In this genetic back-
ground, all three compounds induce replication sufficiently to
be detectable by Western blotting and by TaqMan (Fig. 4).
The different degrees of replication efficiency induced by
compound H479 and compounds A852 and F495 are probably
not a consequence of different potency in the inhibition of p58
formation, which seems to be comparable at 5 M (Fig. 2).
This apparent difference could be explained by considering the
cytotoxicity displayed by compound A852 and especially by
compound F495 at concentrations of 8 M or more (data not
shown). During the experiments designed for the detection of
inhibition of p58 formation, the cells are exposed to 5 M
compound for several hours, whereas they are exposed for 4
days at 8 M during the induction of replication. It is therefore
possible that inhibition of NS5A hyperphosphorylation is nec-
essary for the induction of replication, but different side effects
of the compounds may induce or block other pathways which
may have antagonistic effects on the induction of replication.
Interestingly, the compounds we identified potently inhibit
phosphorylation of NS5A in vitro (Fig. 2, lanes 11 to 13),
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suggesting that they may directly inhibit NS5A-specific ki-
nase(s). However, we cannot exclude the possibility that these
compounds act via the inhibition of upstream kinase(s) that
may also be present in the immunoprecipitate. The spectrum
of cellular kinases inhibited by these agents and whether any of
these kinases is directly or indirectly responsible for NS5A
hyperphosphorylation needs to be clarified by future work.
Our findings support a role for NS5A p58 in down-regulat-
ing HCV RNA replication in cell culture. Based on the present
data, we cannot exclude that the compound(s) we identify act
via the inhibition of the phosphorylation of cellular protein(s)
regulating HCV RNA replication and that inhibition of p58 is
not the actual cause of increased replication. However, we
believe that the present data are supportive of a direct, causal
connection between NS5A hyperphosphorylation and the in-
ability of hepatitis C subgenomic RNA to replicate in cell cul-
ture. This is based on two considerations. First, all of the kinase
inhibitors that we selected for specific inhibition of NS5A hy-
perphosphorylation in cell culture were able to activate RNA
replication. Second, it has been previously reported that sev-
eral adaptive mutations found in the NS5A sequence occur at
conserved serine residues and greatly impair the hyperphos-
phorylation of NS5A (2).
Figure 5 shows two possible models which try to explain the
inhibitory effect of NS5A p58 on HCV replication in cell cul-
ture. According to model A, p56 is necessary for active rep-
lication. In cell culture, p56 is converted to p58 by cellular
kinases and recruits a repressor protein (R) to the replication
complex, thereby inhibiting replication. In the presence of the
specific kinase inhibitors the conversion to p58 is prevented
and the repressor protein R will not be recruited to the rep-
lication complex (upper part of Fig. 5A). There are three
types of adaptive mutations which result in active replication
in cell culture, and the first occurs exactly at the sites of
NS5A hyperphosphorylation (S2197, S2201, and S2204). These
mutations prevent the production of p58 and thus result in
replication in cell culture. This situation would result in a p56-
containing active replication complex, similar to that formed in
the presence of the NS5A hyperphosphorylation inhibitor (Fig.
5A, top panel). The second type of adaptive mutations occurs
in NS5A, however, at sites different from the hyperphosphor-
ylation sites. As a consequence, p58 is still expressed (as in the
FIG. 5. Working model. Replication in cell culture is inhibited in the presence of p58. (A) p58 recruits a repressor protein R to the replication
complex. Upper panel: p56 is converted to the hyperphosphorylated form p58 by cellular kinases, which then binds a repressor protein R. The
presence of this protein complex p58-R results in inactivation of HCV RNA replication. Our selected kinase inhibitors prevent the conversion of
p56 to p58. Lower panel: the presence of adaptive mutations either in NS5A or in other parts of the replication complex prevents the association
of the repressor molecule. (B) p58 is unable to associate with an activator protein. Upper panel: p56 binds an activator protein A and activates
the replication complex. In cell culture, p56 is converted to the hyperphosphorylated form p58 by cellular kinases, which is incapable of association
with the activator protein A. Our selected kinase inhibitors prevent the conversion of p56 to p58. Lower panel: the presence of adaptive mutations
either in NS5A or in other parts of the replication complex enables the association with the activator protein A even in the presence of hyper-
phosphorylation. p56, NS5A p56; p58, NS5A p58; R, repressor protein; A, activator protein. Stars represent adaptive mutations.
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case of Huh7-68). This example is shown in the bottom part of
Fig. 5, to the left of each model. The third type of adaptive mu-
tations does not occur in NS5A, but it occurs in other proteins
which participate in viral replication, e.g., NS3 or NS5B. This
example is shown in the bottom part of Fig. 5, to the right of
each model.
In the latter two cases, adaptive mutations prevent the as-
sociation of the repressor molecule and replication can take
place even in the presence of p58 (Fig. 5A, bottom part). This
model is supported by recent data obtained by Graziani et al.
(9), who demonstrate that coexpression of wt HCV subgeno-
mic replicons together with adapted replicons results in trans-
dominant inhibition of HCV replication in cell culture. Inhib-
itory cellular proteins may be expressed only in transformed cell
lines and be absent in the liver, thus explaining the strict de-
pendence on adaptive mutations for replication in cell culture.
In model B, p58 is not able to interact with an activator
protein (A), which is necessary for replication. Also in this
model, the kinase inhibitors prevent the conversion of p56 into
p58 and binding of NS5A to the activator protein A is main-
tained (upper part of Fig. 5B). In this model, one has to
assume that the latter two types of adaptive mutations restore
protein-protein interactions between NS5A and A, even if
NS5A exists as p58. The latter model is supported by recent
data obtained by Evans et al. (8a).
Production of high levels of p58 may be an artifact of the
subgenomic construct. The expression of the nonstructural
proteins is driven by the strong encephalomyocarditis virus
internal ribosome entry site, and the amount of NS5A p58
during infection in vivo could be significantly lower. Alterna-
tively, the specific kinases and, thus, the formation of p58 are
expressed or regulated differently in cell lines with respect to
the liver, thus disturbing the correct equilibrium between p56
and p58. Different expression of cellular factors could also
explain the strict host dependence of HCV for replication in
cell culture. It would be of great interest to identify the kinases
which are responsible for the formation of p58. A cellular
system in which the expression of this kinase can be regulated
would be an ideal system for the study of the replication of
HCV containing the original, infective wt sequence.
There is an additional interesting observation we would like
to discuss. Figure 4A clearly shows that treatment of cells with
compound H479, A852, or F495 results in a substantial reduc-
tion of p58 but is not completely abolished. Two lines of evi-
dence indicate that complete prevention of p58 formation
eliminates replication. (i) Blight et al. (3) demonstrated that the
mutation S2204I is a very efficient adaptive mutation, whereas
the combination of this mutation together with a second adap-
tive mutation within the hyperphosphorylation sites of NS5A
(S2197P) completely abolished replication. (ii) Incubation of
cells containing a replicon with the adaptive mutation S2204A
with one of our kinase inhibitors also abolishes HCV replica-
tion (Fig. 4A, lanes 20 to 25). In both cases, mutation at one
hyperphosphorylation site significantly reduces the quantity of
p58 and the second event, either a second mutation or inhibi-
tion by our compounds, further reduces p58 formation and
results in a complete block of replication. This observation
suggests, contrary to what has been thought to date, that low
amounts of p58 may in fact be necessary for replication and
that compounds that completely inhibit NS5A hyperphosphor-
ylation could have antiviral activity in vivo.
In conclusion, we have identified compounds that, by inhib-
iting protein kinase(s) implicated in NS5A hyperphosphoryla-
tion, promote replication of nonadapted HCV sequences in
cell culture. This finding points to a role for NS5A p58 in
down-regulating HCV RNA replication in cell culture. To
date, it is not known whether NS5A p58 has a function in viral
replication in vivo or what that function may be. However,
compounds that selectively inhibit NS5A hyperphosphoryla-
tion could be useful tools for the establishment of a bona fide
infection system for HCV in cell culture and could possibly be
a starting point for the development of novel antiviral agents.
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